CRBN and Miyoshi myopathy: Recent molecular studies with lenalidomide- and pomalidomide-resistant MM patients revealed some CRBN molecular alterations (e.g., point mutation, structural variation, copy loss, or exon 10 spliced transcript of CRBN) associated with IMiDs’ exposure [26].